Blood/Bone Marrow Cancer

Loxo Oncology, Inc — A Phase 3 Open Label, Randomized Study of Pirtobrutinib (Loxo-305) versus Ibrutinib in Patients with Chronic Lymophocytic Leukemia/Small Lymphocytic Lymphoma - NO LONGER ENROLLING PATIENTS

European Myeloma Network — A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) - NO LONGER ENROLLING PATIENTS

Breast Cancer

Merck - TroFuse - 011 - A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011) - ENROLLING

Merck - TroFuse - 032 - Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer - ENROLLING

Novartis - A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2− early breast cancer (Adjuvant WIDER) - ENROLLING

Cancer Caregivers

ECARE Study - This study aims to investigate the use of a mobile technology app to monitor the well-being of people caring for someone with cancer over time.

Early Cancer Detection

GRAIL, LLC — The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population - NO LONGER ENROLLING PATIENTS

Precision Medicine— Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnosis of Diseases – Oncology Populations

University of Houston — Detection of circulating tumor cells with UniPro

Cancer caused by Rare Genetic Mutations

Caris Pharmatech Studies — A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Caris Pharmatech Studies — A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations

Caris Pharmatech Studies — A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations

Caris Pharmatech Studies — A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations

Caris Pharmatech Studies — IRONMAN Registry Sub-Study: PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations

Caris Pharmatech Studies — Brightline 2- A Phase II/III, open-label, single-arm, multicentre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type solid tumours-biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors

Caris Pharmatech Studies — An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

Caris Pharmatech Studies — A Phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 in patients with advanced or metastatic solid tumors

Caris Pharmatech Studies — ***REFERRAL ONLY*** A Study of Zenocutuzumab (MCLA- 128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Caris Pharmatech Studies — ***REFERRAL ONLY*** A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Caris Pharmatech Studies — ***REFERRAL ONLY*** A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Caris Pharmatech Studies — ***REFERRAL ONLY*** A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Caris Pharmatech Studies — ***REFERRAL ONLY*** A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Caris Pharmatech Studies — ***REFERRAL ONLY*** An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-175 in Human Leukocyte Antigen-A*02:01- Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation

Caris Pharmatech Studies — ***REFERRAL ONLY*** A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Liver Cancer

Genentech/La Roche — A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma - NO LONGER ENROLLING PATIENTS

Genentech — Kirros HCC - A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis - ENROLLING

Lung Cancer

BMS Rosetta (Phase III study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%) ENROLLING

Pancreatic Cancer

Baylor College of Medicine — PanCan Early Detection Initiative for Pancreatic Cancer - NO LONGER ENROLLING PATIENTS

Prostate Cancer

AstraZeneca Pharmaceuticals — § A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) § - NO LONGER ENROLLING PATIENTS

Pfizer Inc. — Talapro-3: A Phase 3, Randomized, Double-blind, Study of Talazoparib with Enzalutamide Versus Placebo with Enzalutamide in Men with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer - NO LONGER ENROLLING PATIENTS

Skin Cancer

Castle Biosciences — Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous - NO LONGER ENROLLING PATIENTS

Castle Biosciences — Performance of DecisionDx® DiffDxTM-Melanoma in Pediatric Populations - NO LONGER ENROLLING PATIENTS

Castle Biosciences — Evaluation of Clinical Outcomes in Patients with Cutaneous Melanocytic Lesions Tested with a Differential Diagnostic Gene Expression Assay - NO LONGER ENROLLING PATIENTS

Dartnet Institute —Cancer Health Equity Patient-Reported Outcome Performance Measure for Preventative Screening and Counseling

Baylor College of Medicine — Effectiveness of Healthy Habits for Older Adults to Optimize Rehabilitation

MD Anderson Cancer Center — Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation (Rural program expansion) - ENROLLING

Cleerly, Inc. — A Randomized Comparison of Personalized Care Based on Coronary Artery Disease Staging Versus Usual Care for Primary Prevention of Cardiovascular Events § (ENROLLING)

HeartFlow, Inc. - Gamefilm — Using CTA Measures to Define Cardiac Risk In NFL Alumni (ENROLLING)

Novartis - Addvantage — Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD (NO LONGER ENROLLING)

Surgical Innovation Associates — The Safety and Effectiveness of DuraSorb® for Lower Pole Reinforcement in Patients Undergoing 2-Stage Breast Reconstruction - NO LONGER ENROLLING PATIENTS

Dartnet Institute — Individualizing Treatment for Asthma In Primary Care — ENROLLING

Dartnet Institute — A Multi-Center Observational Study: The RECOVER Post Acute Sequelae of SARS-CoV-2 (PASC) Pediatric Cohort Study - CLOSED

Baylor College of Medicine and University of Houston — Precision Medicine for Alzheimer’s Disease and Related Dementias - CLOSED

Baylor College of Medicine — U.S. POINTER: U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk - CLOSED

Eli Lilly - Trailblazer — A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) - NO LONGER ENROLLING

UTHealth — A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation (PRIM-DJ2727) Administered Orally in combination with Standard of Care Therapy for Prevention of Relapse or Intestinal Inflammation in Adults with Ulcerative Colitis

Takeda - Panorama — A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (ENROLLING)

Investigator Initiated — Evaluating the Safety and Effectiveness of Immediate Sequential Bilateral Cataract Surgery: A Comparative Study